Study Supports Delay of CDK4/6 Inhibitors Until Second-Line Treatment in Advanced HR+/HER2- Breast Cancer

被引：0
|
作者：
Rugo, Hope S. [1 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 353
页数：2
相关论文
共 50 条
  • [21] Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response
    Scirocchi, Fabio
    Scagnoli, Simone
    Botticelli, Andrea
    Di Filippo, Alessandra
    Napoletano, Chiara
    Zizzari, Ilaria Grazia
    Strigari, Lidia
    Tomao, Silverio
    Cortesi, Enrico
    Rughetti, Aurelia
    Marchetti, Paolo
    Nuti, Marianna
    EBIOMEDICINE, 2022, 79
  • [22] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [23] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [24] Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer
    Sammons, Sarah
    Shastry, Mythili
    Dent, Susan
    Anders, Carey
    Hamilton, Erika
    CLINICAL BREAST CANCER, 2020, 20 (01) : 1 - 11
  • [25] Therapy of advanced HR+, HER2-Breast Cancer Live professionally longer with CDK4/6 Inhibitor
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [26] Treatment patterns and barriers involving the use of CDK4/6 inhibitors for women with HR+, HER2-breast cancer.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Ackbarali, Tariqa
    Crawford, Rebecca
    Carter, Jeffrey D.
    Greene, Laurence
    Sapir, Tamar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [27] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [28] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [29] Dalpiciclib and tucidinostat in patients with HR+/HER2-advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial
    Wang, Tao
    Zhou, Jinmei
    Wu, Xuexue
    Jiang, Zefei
    CANCER RESEARCH, 2024, 84 (09)
  • [30] Dalpiciclib and chidamide in patients with HR+/HER2-advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial
    Wang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345